Mineralocorticoid Receptor-Associated Hypertension and Target Organ Damage: Clinical Relevance for Resistant Hypertension in End Stage Renal Disease

2012 ◽  
Vol 8 (4) ◽  
pp. 267-275 ◽  
Author(s):  
Yelena Rekhtman ◽  
Andrew S. Bomback
Keyword(s):  
Renal Disease ◽  
Resistant Hypertension ◽  
End Stage Renal Disease ◽  
Clinical Relevance ◽  
Mineralocorticoid Receptor ◽  
Target Organ Damage ◽  
Organ Damage ◽  
Target Organ ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals BILATERAL RENAL ARTERY EMBOLIZATION IN END-STAGE RENAL DISEASE AND RESISTANT HYPERTENSION

2021 ◽  
Vol 39 (Supplement 1) ◽  
pp. e294-e295
Author(s):  
Jan Vaclavik ◽  
Tomas Kvapil ◽  
Marie Cerna ◽  
Vojtech Prasil ◽  
Eva Kocianova ◽  
...  
Keyword(s):  
Renal Disease ◽  
Renal Artery ◽  
Resistant Hypertension ◽  
End Stage Renal Disease ◽  
Artery Embolization ◽  
Bilateral Renal Artery ◽  
Renal Artery Embolization ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals End stage renal disease patients on haemodialysis profiled epidemiologically at medical college of sub-Himalayan region of India

2019 ◽  
Vol 7 (5) ◽  
pp. 1594
Author(s):  
Pankaj Kumar Gupta ◽  
Dinesh Kumar
Keyword(s):  
Diabetes Mellitus ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Organ Damage ◽  
Common Complication ◽  
Common Cause ◽  
Heart Damage ◽  
Medical College ◽  
Stage Renal Disease ◽  
End Stage

Background: Mostly, end organ damage becomes the reason for morbidity and mortality among patients with non-communicable diseases (NCDs) due their chronicity. Derangement of renal function along with brain and heart damage are considered to be a significant problem of NCDs. The objectives of this study were on this background of end stage renal disease (ESRD) as a common complication for common NCDs, present study was planned to study the distribution of responsible NCDs.Methods: Over three-year period, all the cases reported GFR <15ml/min/1.73m2 were studied.Results: Total 100 patients (male:65) were studied with mean age of 51.0±13.0 years. Diabetes mellitus (38.0%), hypertension (28.0%), and glomerulonephritis (16.0%) were three leading cause for ESRD. Idiopathic cause was observed among 12.0% patients. Fifteen percent patients could not survive.Conclusions: NCDs mainly diabetes mellitus and hypertension observed to be most common cause for ESRD.

scholarly journals Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease: Efficacy and Safety

2016 ◽  
Vol 41 (1-3) ◽  
pp. 166-170 ◽  
Author(s):  
Andrew S. Bomback
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Mineralocorticoid Receptor ◽  
Left Ventricular ◽  
Efficacy And Safety ◽  
Mineralocorticoid Receptor Antagonists ◽  
Receptor Antagonists ◽  
Stage Renal Disease ◽  
End Stage ◽  
Esrd Patients

Mineralocorticoid receptor antagonists (MRAs) that block aldosterone's effects on both epithelial and non-epithelial receptors have become a mainstay of therapy for chronic heart failure. Given that cardiovascular events remain the leading cause of death for patients with end-stage renal disease (ESRD), the question of whether these MRAs can be employed in dialysis patients arises. This review summarizes the rationale for blocking aldosterone in patients with chronic and end-stage kidney disease and surveys the data on both the efficacy and safety of using MRAs in the ESRD population. A small but growing body of literature suggests that use of MRAs by ESRD patients is associated with lower blood pressure, reduced left ventricular (LV) mass, and improved LV ejection fraction. Recently, a large randomized trial found an overall 3-year mortality rate of 6.4% in ESRD patients on spironolactone 25 mg daily vs. 19.7% in ESRD patients on no MRA therapy (p = 0.002), without a significantly increased risk of hyperkalemia.

Sign in / Sign up

Export Citation Format

Share Document